Muhammad Asjad Saleem, Medical Doctor at The Indus Hospital, shared a post on LinkedIn:

“The AENEAS2 trial asks a direct, practical question in first-line EGFR-mutated advanced NSCLC: does adding platinum-doublet chemotherapy to aumolertinib improve outcomes over aumolertinib alone?

This open-label, phase 3 RCT enrolled 624 treatment-naive patients across centers in China, all with EGFR-sensitive mutations (ex19del/L858R). They were randomized to aumolertinib with or without pemetrexed plus cisplatin or carboplatin. The primary endpoint was progression-free survival by blinded independent central review.

At a median follow-up of 18.9 months, the hazard ratio for progression or death was 0.47 (95% CI 0.37–0.60) – a substantial risk reduction favoring the combination.

A few caveats deserve attention. The open-label design introduces potential for assessment or management bias. Overall survival data are immature, and follow-up remains relatively short. A reinforced piece of evidence from a randomized setting, but one that still needs survival maturation before the full picture is clear.”

Title: Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Authors: Ziming Li, Jie Hu, Jianhua Chen, Yan Yu, Xiangjiao Meng, Xiaorong Dong, Yanping Hu, Yinghua Ji, Haifeng Liu, Weibo Wang, Fangling Ning, Zhihong Zhang, Chunling Liu, Zhiye Zhang, Qiming Wang, Wei Zheng, Honghai Wang, Xiujuan Qu, Zhenming Chen, Shaonan Fan, Xiaoqing Zhang, Shun Lu